News
FATE
2.410
-4.37%
-0.110
Weekly Report: what happened at FATE last week (0713-0717)?
Weekly Report · 5d ago
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Benzinga · 07/15 12:02
Weekly Report: what happened at FATE last week (0706-0710)?
Weekly Report · 07/13 10:17
Macro Note: The Tech Unwind Grew A Second Leg, And It's Healthcare
Seeking Alpha · 07/11 06:25
Fate Therapeutics (FATE) Gets a Hold from Needham
TipRanks · 07/10 10:55
Fate Gets FDA IND Clearance For FT839 To Initiate Phase 1/2 Trial In Autoimmune Diseases
NASDAQ · 07/10 07:12
Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed
TipRanks · 07/09 15:25
Fate Thera gains after FDA go-ahead to advance CAR-T therapy in clinical studies
Seeking Alpha · 07/09 14:38
CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application For FT839; Enrollment In Phase 1/2 Trial Anticipated In H2 2026
Benzinga · 07/09 13:16
Fate Therapeutics announces FDA clearance of FT839 IND application
TipRanks · 07/09 13:15
Fate Therapeutics' Receives FDA Clearance For Its New Drug Application For FT839
Benzinga · 07/09 12:33
Fate Therapeutics wins FDA IND clearance for dual-target CAR-T candidate FT839
PUBT · 07/09 12:33
FATE THERAPEUTICS - FT839 TRIAL TO INITIALLY TARGET RHEUMATOID ARTHRITIS, VASCULITIS, MYOSITIS, LUPUS, SYSTEMIC SCLEROSIS
Reuters · 07/09 12:30
Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade)
Seeking Alpha · 07/08 15:54
Fate Therapeutics To Demonstrate Data On Its CAR T-cell Product Candidate FT819 At International Society For Stem Cell Research 2026 Annual Meeting
Benzinga · 07/06 12:43
FATE THERAPEUTICS - FT819 ALSO BEING EVALUATED IN SLE; PHASE 2 TRIAL PLANNED IN LUPUS NEPHRITIS
Reuters · 07/06 12:32
Fate Therapeutics reports preliminary FT819 CAR-T data showing skin score improvement in systemic sclerosis patients
PUBT · 07/06 12:31
Weekly Report: what happened at FATE last week (0629-0703)?
Weekly Report · 07/06 10:21
Strong Buy at under $10: The highest Quant-rated bargain stocks right now
Seeking Alpha · 07/03 11:50
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
Barchart · 07/01 15:05
More
Webull provides a variety of real-time FATE stock news. You can receive the latest news about Fate Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.